**Background and objectives:** Anabolic steroids are synthetic derivatives of testosterone, modified to enhance its anabolic actions (promotion of protein synthesis and muscle growth). They have numerous side effects, and are on the International Olympic Committee’s list of banned substances. Gas chromatography-mass spectrometry allows identification and characterisation of steroids and their metabolites in the urine but may not distinguish between pharmaceutical and natural testosterone. Indirect methods to detect doping include determination of the testosterone/epitestosterone glucuronide ratio with suitable cut-off values. Direct evidence may be obtained with a method based on the determination of the carbon isotope ratio of the urinary steroids. This paper aims to give an overview of the use of anabolic-androgenic steroids in sport and methods used in anti-doping laboratories for their detection in urine, with special emphasis on doping with testosterone.

**Methods:** Review of the recent literature of anabolic steroid testing, athletic use, and adverse effects of anabolic-androgenic steroids.

**Results:** Procedures used for detection of doping with endogenous steroids are outlined. The World Anti-Doping Agency provided a guide in August 2004 to ensure that laboratories can report, in a uniform way, the presence of abnormal profiles of urinary steroids resulting from the administration of testosterone or its precursors, androstenediol, androstenedione, dehydroepiandrosterone or a testosterone metabolite, dihydrotestosterone, or a masking agent, epitestosterone.

**Conclusions:** Technology developed for detection of testosterone in urine samples appears suitable when the substance has been administered intramuscularly. Oral administration leads to rapid pharmacokinetics, so urine samples need to be collected in the initial hours after intake. Thus there is a need to find specific biomarkers in urine or plasma to enable detection of long term oral administration of testosterone.
The information on anabolic-androgenic steroids used by athletes to increase their performances is relatively sparse. It is known that bodybuilders follow a typical pattern called ‘stacking’, based on administration of several oral and injectable anabolic-androgenic steroids during cycles lasting 4–12 weeks. The advantage of this practice has been demonstrated recently. The drug dosages range from 250 mg to 3500 mg per week and are therefore up to 40 times the recommended therapeutic dosage. However, some studies have described the effect of polypharmacy practice at therapeutic doses in weight lifters, and endurance and sprint athletes.

Physically, administration of anabolic-androgenic steroids may affect behaviour. Increased testosterone levels in the blood are associated with masculine behaviour, aggressiveness, and increase of sexual desire. Increased aggressiveness might be beneficial for athletic training, but might also lead to overt violence outside the gym or the track. Other side effects of anabolic-androgenic steroids are euphoria, confusion, sleeping disorders, pathological anxiety, paranoia, and hallucinations. Some of these psychological effects could be beneficial for athletes by improving their performance. Indeed, it is more and more often suggested that the intake of small doses of anabolic-androgenic steroids, particularly testosterone, could lead to a lower fatigue levels, a better recovery, and therefore to higher training charge, and finally to a faster increase in physical performance. In a recent controlled study including a placebo group, the effect of multiple oral doses of testosterone undecanoate on mood state during one month of intense endurance training was assessed. It emerged that multiple oral intake of testosterone undecanoate could have an impact on recovery from physical strain in a hard training period. In some cases, however, it appeared that mood changes was the result of a placebo effect.

**ANABOLIC STEROID TESTING**

**Background**

The medical commissions of major international sport federations and of the International Olympic Committee (IOC) have been concerned over the misuse of doping agents in the sports community since the beginning of the 1970s. At that time, these commissions developed a dope control procedure whose fundamental elements are still valid today:

1. Selection of athletes
2. Urine sample collection procedure
3. Analysis of the A sample in an accredited IOC laboratory
4. If the A sample gives positive analytical results, analysis of the B sample in the same accredited laboratory.

The hearing of the athlete is then organised by the medical commission, where the eventual sanctions against the athlete are decided.

International organisations have established a list of substance classes and methods that athletes are forbidden to use during competition and training. The latest list established by the World Anti-Doping Authority (WADA) for 2006 includes two types of steroid:

- the typically exogenous steroids, of which the main examples are given in fig 2
- the typically endogenous steroids—for example, androstenediol, androstenedione, dehydroepiandrosterone (DHEA), dihydrotestosterone, testosterone and related substances.

According to the 2004 WADA statistics, about 36% of the positive analytical finding declared by the accredited anti-doping laboratories concerned anabolic-androgenic steroids. Among the 1191 positive cases, it is worth mentioning that testosterone and nandrolone were the most used substances (33% and 29% of the cases, respectively).
Testing for anabolic agents in the urine of athletes was implemented on a large scale during the 1976 Olympic Games in Montreal and was mainly based at that time on radioimmunoassay techniques. The techniques for the identification and characterisation of steroids and their metabolites in the urine have improved considerably during the past two decades. This improvement is largely due to the use of gas chromatography-mass spectrometry (GC-MS) techniques. Today, most anti-doping laboratories use techniques based on the solid phase extraction of the urine sample, followed by chemical modifications prior to GC-MS analysis. The confirmation procedure in an anti-doping analysis consists of demonstrating unequivocally that there is a correspondence between the GC and MS properties of the anabolic agent or its metabolite with those of an authentic pure standard or of a reference excretion study.

The T/E ratio
Detection of exogenous substances means identifying the parent compound or at least one metabolite. Nevertheless, with substances that are produced endogenously, such as testosterone, the presence of the substance alone cannot be considered to be an offence by itself. Moreover, a cut-off value for testosterone concentration cannot be used because of large observed interindividual and intraindividual urinary concentrations of the steroid. However, intake of testosterone causes characteristic changes in the pattern of steroids excreted in the urine. Based on studies of athlete populations, the IOC adopted in 1983 a ratio of testosterone to epitestosterone glucuronides (T/E) with an authorised upper limit of 6.0 as a criterion for the administration of testosterone. Since epitestosterone is only a minor product of the metabolism of testosterone and does not increase after testosterone administration, the resulting effect is an increase in the T/E ratio. In several studies, the distribution of ratios in Caucasian athlete populations shows generally a mean T/E ratio less than 2.0, whereas in Asian populations the mean T/E ratio is significantly lower. The IOC rules clearly indicate that a T/E ratio greater than 6.0 constituted an offence unless there was evidence that this ratio is due to physiological or pathological conditions—for example, low epitestosterone excretion, androgen producing tumour, and enzyme deficiencies. In addition, it has been observed that hepatic metabolism of steroid hormones may be altered by administration of substances as ethanol with the resulting effect of modifying significantly the T/E ratio.

Other urinary tests such as ketoconazole test and the testosterone glucuronide to luteinising hormone (T/LH) ratio have been developed to deter doping with testosterone or a precursor. However, there is still a lack of a reference method for measuring and identifying LH and therefore the T/LH ratio is less effective in meeting legal challenges. Detection of testosterone esters in plasma and hairs have also been suggested as promising solutions to deter doping with injectable preparations of testosterone esters. Nevertheless, doping controls are still limited on urine samples for detection of doping with these substances. Regarding hair analysis, it has been found that these T esters are poorly stored in hairs and therefore only massive and repeated use of these substances may be detected in this biological matrix.

Before a sample is declared as consistent with doping with testosterone or a precursor, further investigations are conducted, such as a longitudinal study of the urinary T/E ratio. As a first step, comparison with previous values should be done; if no previous values are available, several additional urine samples are analysed over a short period of time. This longitudinal study may represent a useful tool for discriminating the false positive (naturally elevated T/E ratios) results from those due to manipulation of the urine. According to guidance given by WADA in 2004, urine samples should be now submitted to isotopic ratio mass spectrometry (IRMMS) if the T/E is greater or equal to 4.0 and testosterone, testosterone metabolites, epitestosterone, and DHEA concentrations are greater than fixed cut-off concentrations.

Carbon isotope ratio
Even if longitudinal study gives good quality information on the potential steroid profile manipulation, there is a lack of definitive proof for the exogenous application of natural steroids. One possible way of solving this problem is the ratio of the two stable carbon isotopes $^{13}$C/$^{12}$C, which can allow the differentiation of natural and synthetic steroids. As exogenous testosterone and precursors contain less $^{13}$C than their endogenous homologues, it is expected that urinary steroids with a low $^{13}$C/$^{12}$C ratio originate from pharmaceutical sources. Endogenous steroids are produced from cholesterol in the body. Cholesterol is derived from an average of a wide variety of feed vegetal and animal precursors or synthesised from precursors of feed origin.

In plant tissue, the main source of variation in $^{13}$C/$^{12}$C isotopic ratio is derived from the different photosynthetic pathways for carbon dioxide fixation. Plants incorporate carbon dioxide via photosynthesis by three different mechanisms: the Calvin cycle ($C_3$) pathway, the Hatch-Slack ($C_4$) pathway and the crassulacean acid metabolism (CAM) pathway. The $C_3$ pathway results in a large change in the carbon isotope proportions relative to atmospheric carbon dioxide and hence discriminates more strongly against the heavier isotope $^{13}$C compared with the $C_4$ pathway. Main representatives of $C_3$ group are wheat, rice, potato, barley, grape, oats, and sugar beet, whereas maize, sugar cane, millet, and pineapple are the important species of the $C_4$ group. The difference in the $^{13}$C enrichment of food products in the diet and even in the food chain is caused by different contribution of naturally $^{13}$C-enriched constituents. Because maize, millet, and sugar cane ($C_4$ plants) are the common food ingredients in some areas of Africa, it is expected that the basic $^{13}$C enrichment of the body store will be high for local populations. It is known that urine samples collected from a country such as Kenya have a higher content of $^{13}$C in steroids than western or oceanian countries.

The method for determining the isotopic composition of the relevant analyte includes gas chromatography, a subsequent combustion to CO$_2$, and finally, mass spectrometric...
analysis of this gas in a special multi-collector mass spectrometer (gas chromatography/combustion/isotope ratio mass spectrometry, GC/C/IRMS). The $^{13}C/^{12}C$ value of testosterone or that of its metabolites will be measured and compared with that of urinary reference steroids within the sample to take into account variation in an athlete’s diet. In addition, it should be emphasised that the $^{13}C/^{12}C$ value of these endogenous reference compounds should not be affected by steroid administration. The result will be reported as consistent with the administration of a steroid if a significant difference is observed between the $^{13}C/^{12}C$ values of testosterone metabolites and the endogenous reference compound. Following population studies, a different cut-off for positivity was stated in 2004 by the WADA Laboratory Committee. If the IRMS study does not readily indicate exogenous administration, the result should be reported as inconclusive, and if necessary further longitudinal studies are performed.

It is also worth mentioning that an IRMS method for determining the $^{13}C/^{12}C$ values for urinary epitestosterone was developed to provide much needed additional support for the detection of doping with epitestosterone. Epitestosterone has no clinical use and is not available as a pharmaceutical drug. This compound is prohibited by sport authorities because its administration will lower the urinary T/E ratio, a marker of testosterone administration.

CONCLUSION

Although knowledge of androgen steroid metabolism has increased during the past decades and analytical guidance has been provided by sport authorities, detection of doping with testosterone remains a challenge in sport. Clearance of orally administered testosterone esters is rapid, and hence drug testing analysis of the urinary concentration can only be performed in the first hours after administration. In order to increase the sensitivity of testosterone esters detection, further investigations have to be conducted for identification of specific biomarkers of this class of doping agent. Beside the difficulty of their detection in urine samples, these substances are used for positive effects on mood states, and also to lower the level of fatigue.

Authors’ affiliations

C Saudan, N Baume, N Robinson, L Avois, P Mangin, M Saugy, Swiss Laboratory for Doping Analyses, Institute of Legal Medicine, Lausanne, Switzerland

Competing interests: none declared

REFERENCES
